About Cytoki

Cytoki’s leadership brings together deep expertise in IL-22 biology, lipidation technology, and the discovery and clinical development of novel drugs to address metabolic disease. We are uniquely positioned to leverage the potential of IL-22 as a new treatment paradigm for metabolic diseases, including obesity, and type 2 diabetes, as well as conditions characterized by epithelial injury, such as inflammatory bowel disease (IBD).